Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics

4 Feb 2023

Abstract excerpt

BACKGROUND: Oncogenic overexpression of integrin-β7 (ITGB7) in cases of high-risk multiple myeloma (MM) was reported to promote enhanced interactions between neoplastic plasma-B cells and stromal cells to develop cell-adhesion mediated drug resistance. METHODS: Expression profiles of adhesion related genes were analyzed in a cohort of MM patients containing major IgH translocations or hyperdiploidies (HY),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Multiple Myeloma Research and Treatments
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36737807
DOI: 10.1186/s13148-023-01433-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogeneticsPMID 36737807Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myelomaSemantic proximity Read ↗

Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple MyelomaSemantic proximity Read ↗

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myelomaSemantic proximity Read ↗

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myelomaSemantic proximity Read ↗

Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myelomaSemantic proximity Read ↗

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSemantic proximity Read ↗

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myelomaSemantic proximity Read ↗

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.Semantic proximity Read ↗

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity Read ↗

Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple MyelomaSemantic proximity Read ↗

Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling moleculesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.